Abstract

Introduction

The counterfeit phenomenon is a largely under-reported issue, with potentially large burden for healthcare. The market for counterfeit drugs used in sexual medicine, most notably type 5 phosphodiesterase inhibitors (PDE5i), is rapidly growing.

Aims

To report the health risks associated with the use of counterfeit medications, the reasons driving their use, and the strategies enacted to contain this phenomenon.

Methods

A systematic scoping review of the literature regarding counterfeit PDE5i was carried between January and June 2021, then updated in August 2021.

Main Outcome Measure

We primarily aimed to clarify the main drivers for counterfeit PDE5i use, the health risks associated, and the currently available strategies to fight counterfeiters.

Results

One hundred thirty-one records were considered for the present scoping review. Production of fake PDE5i is highly lucrative and the lacking awareness of the potential health risks makes it a largely exploitable market by counterfeiters. Adulteration with other drugs, microbial contamination and unreliable dosages make counterfeit medications a cause of worry also outside of the sexual medicine scope. Several laboratory techniques have been devised to identify and quantify the presence of other compounds in counterfeit medications. Strategies aimed at improving awareness, providing antitampering packaging and producing non-falsifiable products, such as the orodispersible formulations, are also described.

Clinical implications

Improving our understanding of the PDE5i counterfeit phenomenon can be helpful to promote awareness of this issue and to improve patient care.

Strengths & Limitations

Despite the systematic approach, few clinical studies were retrieved, and data concerning the prevalence of counterfeit PDE5i use is not available on a global scale.

Conclusion

The counterfeit phenomenon is a steadily growing issue, with PDE5i being the most counterfeited medication with potentially large harmful effects on unaware consumers.

Introduction

The efficacy of type 5 phosphodiesterase inhibitors (PDE5i) has been verified by countless studies, and indeed these drugs have been included as the first-line treatment for the management of erectile dysfunction (ED).1 It is therefore unsurprising that the general population has heard about these drugs, including patients with a very limited awareness of their sexual health. However, the widespread knowledge of these drugs in media and social networks2 has made them widely adopted lifestyle drugs,3 thus drawing the attention of counterfeiters.

The exact meaning of “counterfeit medicine” has been disputed in the last decades. The definition proposed by the World Health Organization (WHO) in 2009, which defined such drugs as “deliberately and fraudulently mislabeled with respect to identity and/or source”, was recently revised in 2017, with an added warning concerning the exact composition of the drug (“deliberately or fraudulently misrepresent their identity, composition or source”).4 The WHO also proposed the definition of “substandard” drugs for all those products that are authorized on a local basis but fail to meet quality standards for or specifications.4 While theoretically these definitions could be helpful in the identification of products of dubious origin, they have not been universally accepted, and there seems to be no worldwide policy aimed to fight the ever-increasing phenomenon of counterfeiting. National regulatory agencies have seldom joined efforts on an international scale, and the consequences for counterfeiters are generally less severe than one would expect.58 For practical purposes, counterfeit drugs are those without any active pharmaceutical ingredients (APIs), or with different dosages of the intended APIs, or with fake packaging. Such drugs often include other pharmaceutical products than those intended, possibly increasing the health risks of consumers.9

In this scenario, experts in sexual medicine and andrologists should not underestimate the phenomenon of counterfeit medications. Counterfeit drugs used to improve sexual function represent a growing issue for public health, and while several strategies have been developed to fight counterfeiters, the market is constantly increasing. In the present systematic scoping review, we aimed to provide a thorough overview of the extent of this problem, answering the following questions: why do patients choose to actively look for counterfeit products, rather than following the traditional complaint-diagnosis-therapy track? What are the risks associated with counterfeit medications, and particularly with counterfeit PDE5i? Which are the possible strategies to prevent these risky behaviors?

Methods

We systematically reviewed all publications found on PubMed and Google Scholar using the following search string: (pde5 or phosphodiesterase or sildenafil or tadalafil or vardenafil or avanafil) and (fake or counterfeit or falsified). The initial systematic search was performed between January and June 2021, and a subsequent update was performed in August 2021. Results were limited to full articles written in English and/or Italian, without any date limitation and with no additional inclusion or exclusion criteria. The search string was purposely vague in order to adequately perform a scoping review – that is, “to identify knowledge gaps, scope a body of literature, clarify concepts or to investigate research conduct”.10 References of included papers were also scanned looking for additional content which would have been otherwise missed by our search queries. We also searched among reports by Organizations and Regulatory Agencies, such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) in order to retrieve additional material concerning the topic of counterfeit medical products, including, but not limited to, PDE5i.

Results

As shown in Figure 1 , following removal of duplicate results, 202 unique record were thus found, among which 12 were not assessed due to language constraints, 18 had no full-text available (including 5 conference abstracts) and 5 were not research papers (one conference program, one application note, and three investigation reports). One hundred sixty-seven full texts were thus evaluated, and 36 papers were considered off-topic for the present study. The remaining 131 papers and book chapters were considered for the present scoping review: among these results, 96 investigated available techniques for the analysis of counterfeit medical products,5,11105 6 were case reports53,92,106109 (two of which also provided information on chemical analysis of the counterfeit drug), 7 were editorials,7,110115 22 were reviews or guidelines,6,8,9,116134 and 2 studies reported patterns of use of counterfeit drugs in two different countries, namely a retrospective study in Brazil135 and a prospective study in Japan.136 According to our results, we identified the following four main topics for research: worldwide prevalence of counterfeit products, including PDE5i; health risks associated with the use of counterfeit PDE5i and other pro-erectile medications; social and psychological reasons for the counterfeit PDE5i phenomenon; and strategies to fight counterfeiting in sexual medicine (Figure 2 ).

Flowchart of the papers included in the present systematic scoping review. *: two papers were included in both categories.
Figure 1

Flowchart of the papers included in the present systematic scoping review. *: two papers were included in both categories.

Counterfeit PDE5 inhibitors: pending issues.
Figure 2

Counterfeit PDE5 inhibitors: pending issues.

Discussion

The Numbers of the Counterfeits in the World. Regional Differences

Drug counterfeiting has been a known phenomenon for many centuries, with reports of fake antimalarial drugs being sold since the 17th century.9 The real extent of counterfeit drugs being presently produced and sold is impossible to ascertain,112,115,117,124,125 and even countries with no reported findings of counterfeited products are virtually non-exempt from this issue. The most recent WHO Global Surveillance and Monitoring System (GSMS) report on substandard and falsified medical products4 highlights several factors limiting the reporting of inadequate products, such as low detection levels, cultural reasons to refrain from reporting, and the already mentioned blurry definition of counterfeit products in several countries. As an example, no reports were addressed between 2013 and 2017 to the WHO GSMS by many countries, including Canada, Portugal, and Australia: however, this is not an indication of no counterfeit medications being illegally sold, but rather that no reports were escalated to the WHO, possibly being investigated and managed internally. Furthermore, as counterfeit products are generally produced abroad and sold through the internet,125 reports are closer to a depiction of the international situation than to the snapshot of the reporting country.65 It is also worth mentioning that in order to adequately address the issue of counterfeit medications, the involvement of several authorities (e.g. customs offices and police, but also healthcare professionals) actively searching for counterfeit products is necessary114: quoting the WHO GSMS, “The more one looks, the more one finds”.4

The African region accounts for almost 42% of the reports addressed to the WHO GSMS between 2013 and 2017,4 with antibiotics and antimalarials being the most counterfeited medical products, due to the high request in low-income, developing countries.15,130,133 In many cases, individuals in poor economic conditions prefer to buy drugs at a cheaper price, despite being aware of the potential risks to their health, under the assumption that they would be better than the absence of any treatment whatsoever.9 In some emerging countries, the prevalence of counterfeit drugs is estimated to be reaching up to 60%.121

Lifestyle drugs are the most counterfeited products found by police investigations in developed countries, such as in Europe and North America, with PDE5i having the largest share of the market and other appearance and performance enhancing drugs, such as anabolic androgen steroids, being close second.65,73,125,126,135 For the largest part, the high prevalence of counterfeit PDE5i can be related to the well-known efficacy of these drugs, their supposed safety, and their commercial success.45,126 Indeed, analysis of urban wastewater showed that in some European cities the concentration of sildenafil and its urinary metabolites was significantly higher than expected based on prescriptions, suggesting large illegal sources of drug acquisition.70 While the FDA reports incidence of counterfeit drugs in the United States to be rare, relatively to the large number of prescription drugs used,137 the amount of investigations due to drug fraud have been on the rise at least since 2000.8 In Europe, almost 36 million counterfeited sildenafil tablets were sold between 2004 and 2008,6 and in 2010 up to 2.5 million men were likely assuming “fake” sildenafil tablets, accounting for about 50% of its total use.8 In Brazil, 80% of reports in regards to counterfeit drugs between 2007 and 2010 included counterfeit sildenafil or tadalafil135; in Japan, where men with ED can legally buy medications from abroad for private use, the online market for counterfeit PDE5i has grown exponentially, with reports from 2010 describing the market for counterfeits PDE5i being 2.5 larger than that of genuine PDE5i.120,136 PDE5i are an extremely lucrative market for counterfeiters, as the revenue is estimated to be up to 2000 higher than that of cocaine while having much lower risks for the producers.58,124

The Risks of the Black Market for the Unaware User

The use of counterfeit medical products carries a significant risk for the user's health, due to several factors which are not always immediately obvious to the consumers themselves.

First and foremost, the largest health threats come from the use of wrong dosages of the intended drug – either too low to be effective, or at excessively high and possibly toxic levels, with large variations in drug contents.6,59,67,125,129 The risk of overdosage of the medication is also possible for products with low content of the API, as consumers might be taking more than one tablet to achieve the desired effect.6,18 However, in order to generate revenue and refrain the buyer to search for more efficacious products, counterfeiters are generally likely to use include the main API or similar active ingredients, or, as reported below, to add other APIs aiming to increase the efficacy.7

Counterfeit products are often produced in poor quality laboratories, resulting in the presence of residual solvents and contaminants in the finished product.6,45,62,125,128,129 An analysis of counterfeited or illegal PDE5i collected between 2005 and 2011 in Italy reported that excipients were different than expected from a genuine product in 80% of analyzed samples, with presence of potentially toxic compounds in 17% of tablets.19 These substances include ethanol, acetone, tetrachloromethane and dicloromethane63 as well as paints and printer inks,8 potentially harmful to the consumers as well as to the environment. Salts and compounds used during the preparation of the drugs can alter the pharmacodynamic properties of the main API,91 and in some cases can act as APIs on their own, as reported for 2-Mercaptobenzothiazole-contaminated sildenafil tablets.26

Another potential risk comes from the use of different APIs in the preparation of the counterfeited product, either voluntarily, in order to increase efficacy,59 or involuntarily, following inadequate quality control. For treatments used in sexual medicine, agents voluntarily added to increase efficacy include different drugs belonging to the same family (eg, vardenafil being added to sildenafil tablets40), or drugs potentially “synergistic” to the main product (eg, sildenafil being added to dapoxetine tablets57). While in theory the effects of the combined drugs might lead to increased efficacy, the risk of developing side effects is similarly increased; additionally, the association of these drugs is not recommended by any of the regulatory agencies or guidelines.117,138-142 PDE5i can also be added to “sexual enhancement” herbal remedies in order to increase the efficacy of the products6,30,47,76,79,116,118: as an example, a herbal remedy sold as a “sexual enhancer” was found out to contain sildenafil and tadalafil in dosages up to 200 times the suggested dose.106 Such high dosages, together with the presence of toxic solvents, are possibly leading to harmful effects for the unsuspecting user: indeed, acute liver injury and ischemic stroke have been reported following the intake of herbal remedies contaminated by sildenafil and/or tadalafil.108,122,128 Likewise, analogues of PDE5i have been added to “functional foods” (eg, pseudovardenafil and hydroxyvardenafil in dietary supplements79) and counterfeit medications (eg, hongdenafil, homosildenafil and hydroxyhomosildenafil in counterfeit sildenafil82) to enhance the effects: safety and efficacy profiles of such substances have not been adequately investigated, possibly resulting in hazardous effects for the unaware user. Similar considerations can be made for dietary supplements sold with the claim to improve sexual health, whose adulteration can pose a risk to consumers’ health.23,128 On the other hand, adulteration with other APIs not intended to be included in the product has the potential to generate unwanted side effects according to the contaminating drug. A clear picture of the potential risks associated with the use of contaminated drugs comes from an outbreak of hypoglycemia occurring in 2008 in Singapore: 150 nondiabetic men were admitted to public hospitals for hypoglycemia due to adulteration of both counterfeit tadalafil tablets and herbal remedies with glibenclamide, with lethal outcome for four of the involved consumers.143 Following this first episode, several other occurrences of contamination with glibenclamide has been reported for both counterfeit PDE5i medications53 and herbal remedies.107,109 Adulteration of PDE5i with paracetamol or metronidazole8 has similarly been reported. This phenomenon is not limited to drugs or remedies being taken to improve male sexual health: contamination of slimming products, skin creams, and analgesics38 has also been reported, with orlistat, sibutramine, corticosteroids, and other appearance and performance enhancing drugs being added without being declared. Herbal supplements containing flibanserin and tadalafil have also been identified.75 In some cases, the adulteration is seemingly accidental and a consequence of inappropriate laboratory procedures, as occurring with glibenclamide, although in many situations the inclusion of another API is voluntarily performed to enhance the efficacy of the treatment. Given that most, if not all, classes of medication are able to exert a tangible effect on sexual health – antidepressants, antihypertensives and opioids being known examples of this phenomenon – the issue of drug adulteration is extremely relevant for sexual medicine specialists.6,113,115

Microbial growth resulting from production of the counterfeited drug in nonsterile laboratories has also been reported.69 Several bacteria able to cause infection, among which the most common were from the Bacillus genus, were identified: on the other hand, genuine products do not show signs of contamination.69 This difference is hardly surprising, giving the strict good manufacturing practices required by regulatory agencies for the authorization and licensing of medical products and the generally poor hygienic conditions of clandestine laboratories.6,9,65,69

Health Risks of Unsupervised Use of Counterfeit PDE5i

Another issue, largely unrecognized by most subjects buying counterfeit products online, lies in the unsupervised use of the intended API. Concerning treatments for sexual dysfunctions, while PDE5i have a generally good safety profile, clinicians prescribing these drugs should be well aware of the potential contraindications in selected patients, such as those undergoing nitrate therapies: individuals buying these drugs online might not be aware of the potential risks associated with other concomitant treatments.112,115 Cases of sexual activity related deaths have also been reported due to non-prescription use of PDE5i in high-risk patients, partly because of underlying conditions, and partly because of the use of combined use of multiple PDE5i.144 Some websites only provide high dosages of PDE5i, without mentioning the suggested “starting” dose for any naïve patient.57 Additionally, first-line treatments for ED include pursuing a healthier lifestyle, such as by limiting alcohol intake, reducing harm from tobacco smoking and performing physical exercise112,145,146: individuals buying “sexual enhancers” online, or getting them from friends without any prior clinical evaluation, are generally less aware of the pathophysiology of sexual dysfunctions115 and thus less likely to investigate for any underlying condition, such as endocrine dysfunctions including hypogonadism147,148 and diabetes,138,149,150 or metabolic and cardiovascular diseases,150152 possibly resulting in ED.136,153 The unsupervised use of PDE5i might therefore reduce the rate of diagnosis for ED-associated diseases.8,115,154 Worryingly, this phenomenon is not limited to drugs for sexual dysfunctions: indeed, several reports suggest that internet can be used in order to circumvent doctors’ opinions and consultations also concerning other conditions.7,8

Another fundamental professional help is skipped when buying online counterfeit PED5is, that is, that one from the pharmacist.123 The selling of sildenafil out of the counter in countries as United Kingdom and Norway ensured a higher degree of accuracy and specificity in the patient and pharmacist decision-making around suitability for use.155 Moreover, it could be inferred that the peculiar pharmacist-client relationship may result in a more “horizontal” than “vertical” information which is to be bona fide considered particularly efficient when complex therapeutical strategies, such as changes in lifestyle, have to be prescribed.123 However, a recent online survey on 668 Italian pharmacists demonstrated that they have limited knowledge about falsified drugs in general, with only 24.5% of respondents failing to indicate that falsified drugs may contain less or different ingredients, 46.4% less and/or different excipients, and 72.3% ignoring that falsified drugs may be lethal.156 One in 3 respondents did not know about falsified drugs in Italy. These findings demonstrated that, without targeted, continuous and strong educational interventions the pharmacists’ community could be hardly considered a resource against the risk of counterfeits in the field of ED treatment.123 The need of specific education of the pharmacist in identifying falsified medicines has been found as a major strategy also in United Kingdom.157

Additionally, while buyers are often enticed by the possibility of getting the desired drug at a cheaper price, this is rarely the case, due to several “hidden” costs, including shipment, customs clearance, online medical consultations, additional packaging and so forth112; additionally, in the case that no products are received by the buyer, there is little, if any at all, chance to retrieve all money spent. This is, of course, on top of the potential risks associated with sharing payment information on “shady” websites, such as “phishing” and other forms of digital threats.

The Psychological and Social Reasons of the Phenomenon

From a distance, it would be easy to identify 2 categories of “victims” of counterfeit drugs: patients who receive a prescription from a healthcare specialist and look for cheaper alternatives to pharmacies and individuals who seek treatments without any prior consultation.7 This generalization is fitting for all kinds of counterfeit medications, not being limited to drugs for sexual dysfunction only7: however, several factors contribute to the ever-growing market for falsified PDE5i.112,121

First and foremost, as previously reported, the high success of the genuine drugs made them quite recognized even to the general population and widely adopted worldwide.116,121,129 ED is a frequent complaint in aging men,158 and it is largely expected that many elderly people would look for treatment in order to improve their sexual health; however, there is compelling evidence that some individuals would take such drugs for recreational purposes in the absence of medical suggestion, even among younger men.129,136,159-162 Considering the social stigma for ED, it is unsurprising that many subjects would prefer buying online, in full anonymity, rather than buying in person18,65,117,129: indeed, PDE5i have the highest prevalence among drugs bought through the internet,8,125,129 and younger subjects are indeed those who buy drugs online more frequently.112 Additionally, most fraudulent websites do not require prescriptions,65 nor do they provide “remote” medical consultations.8 The convenience of being able to buy the drugs at every time of the day and from mobile devices is another possible reason driving people towards online pharmacies or pseudo-pharmacies,116 and in more recent days also toward other markets, such as social media.2,113 Additionally, as the costs of these drugs are among the chief reasons for drop-out,131,163 it is unsurprising that consumers might be looking for cheaper alternatives.

Herbal remedies are often promoted as “natural” supplements to improve sexual health, therefore giving to the unaware user the false perception of a safer and more reliable product with no side effects.6,43,116,128 Once again, adulteration with PDE5i – performed in order to provide some effects, and hence generate repeat business7 – makes the use of these products quite unsafe for consumers, who might develop severe side effects with little awareness of the medications they're involuntarily taking. Additionally, although several well conducted in vitro and in vivo studies demonstrated a role of herbal remedies in the management of male sexual health,164169 the potential effects of these remedies are largely disputed.116

While this is a relatively smaller phenomenon, some reports of counterfeit drugs being legally sold has been collected,73,111 highlighting the potential of counterfeit products to reach the “regular” supply chain. It is, therefore, necessary to educate potential consumers in order to prevent them from falling prey to counterfeiters.

Compounded and Counterfeit Medications

It is not uncommon for patients to ask for compounded medications, that is, drugs prepared in a pharmacy laboratory by trained professionals; such products are clearly different from counterfeit medication, being the application of pharmaceutical expertise to provide tailored treatment. Historically, drug manufacture and preparation were among the chief tasks for a pharmacist in the past. As of today, the need for higher quality standards and for mass production has moved this process from pharmacies to industries; however, compounded medications are still prepared for tailored treatment of patients with particular needs. The FDA defines drug compounding as “the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient”.170 In Europe, the term “pharmacy preparation” is also used; European laws distinguish the ‘magistral formula’ (“any medicinal product prepared in a pharmacy following a prescription for an individual patient”) from the ‘officinal formula’ (“any medicinal product which is prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia that is intended to be supplied directly to the patients served by the pharmacy”).171 Broadly speaking, compounded drugs are not as closely monitored as industrial products and do not follow good manufacturing practices, and are therefore not approved by Regulatory Agencies; however, as they fill a “niche” and can potentially allow or improve treatment in well-defined populations, pharmacy preparations can be used in selected settings.171 Indeed, caution when using these drugs is necessary, as the use of pharmacy preparations has been associated to some of the risks reported for counterfeit medications, such as the presence of contaminants: in 2012, an outbreak of meningitis, with 64 deaths and 689 nonfatal complications172 occurred following Aspergillus fumigatus contamination of methylprednisolone vials produced by the New England Compounding Center (NECC).173 Likewise, compounded drugs might contain wrong dosages of the intended drug, possibly resulting in unreliable clinical effects. Despite these similarities, it is clear that counterfeit medications and compounded drugs are different products, with the former being produced by generally untrained individuals with no concerns for the users’ health and the latter being instead carefully manufactured by trained professionals in order to address an unmet need.

The Costs of Counterfeit Medication for Society and Public Health

The use of counterfeit medication has several costs for society and public health,127 from the damage to intellectual property to the already reported harmful effects to the consumer.

Damage to intellectual property – similarly to what occurring for software piracy or counterfeiting of non-medical products, such as toys, apparel or luxury goods – has hidden costs which are rarely clearly evident to the consumer,127 such as the loss of revenue for the producer, the reduced availability of funds for research and development (R&D), and often loss of jobs for affected companies – “When Banks Fail, It Is Seldom Bankers Who Starve.”174 While this is true for all societies targeted by counterfeiters, it becomes of paramount importance for medical companies, which spend large part of their revenue on R&D127 and wouldn't find it profitable to engage in further research projects only to have them “stolen” by counterfeiters. As investments in R&D could be used to reduce prices of current products or to develop new drugs, a vicious cycle might develop in which request for cheaper, counterfeited products actually prevents companies from providing cheaper, effective products.

Harmful effects on consumers, on the other hand, might be more evident to the general population. First and foremost, money spent on a nonworking treatment is effectively lost, result in a direct economic damage to the user; the same would apply for unsuccessful transactions in which despite the payment, no product is received by the buyer.127 The risks of unsupervised use of counterfeit drugs have already been described; additionally, use of tablets devoid of any active ingredients can have potentially serious consequences, as in the absence of any treatment, the underlying condition might progress, leading to worse clinical outcomes for the unaware user. On top of that, the public health costs of undesired effect of contaminants – whether microbial, chemical, or APIs – should also be considered: as occurred with the glibenclamide contamination,143 use of counterfeited medication might also have potentially fatal consequences.144 Liver damage, ischemic stroke, and kidney failure have been reported following accidental intake of toxic compounds or undeclared APIs: management of these conditions further weighs on public health.

Public Education: A Necessary Strategy in the Fight Against Counterfeiters

Based on current evidence, it can be assumed that the counterfeit market is flourishing because of an ever-increasing demand, largely supported by the lacking awareness of the health risks and sub-standard efficacy of these products.133 As a consequence, strategies acting to reduce demand, mostly by raising awareness of the potential issues, could be a useful weapon in the fight against counterfeiters. Education thus becomes the most reliable way to prevent the spread of the counterfeit phenomenon, and physicians should always suggest their patients not to buy medications online.117 Public education, however, is a daunting and complex challenge for public health, requiring the involvement of international authorities and the development of a shared policy to fight the counterfeit phenomenon. Indeed, in 2006, the WHO has launched the International Medical Products Anti-Counterfeiting Taskforce (IMPACT), a network of experts aiming to halt the production and marketing of counterfeited medical products,6 and likewise educational campaigns have been promoted in the United States137 and in Europe.175 The relevance of such multifaceted approaches has recently been rekindled by the illegal marketing of counterfeit COVID-19 vaccines,176 highlighting the general disregard counterfeiters have for the health of patients. The EMA and the European Directorate for the Quality of Medicines (EDQM) are in first line in facing counterfeits and in studying strategies to reduce the epidemy of falsified medicinal products. Henceforth, the Council of Europe is currently supporting an international convention dealing with the criminal law field on counterfeiting of medical products and similar crimes involving threats to public health.177 The States Parties must criminalize: (i) the manufacturing of counterfeit medical products; (ii) supplying, offering to supply and trafficking in counterfeit medical products; (iii) the falsification of documents; (iv) the unauthorized manufacturing or supplying of medicinal products and the placing on the market of medical devices which do not comply with conformity requirements. The chart of signatures and ratifications shows that, as of April 20, 2021, some Members did not sign nor ratify the document yet (Andorra, Azerbaijan, Bulgaria, Czech Republic, Estonia, Georgia, Greece, Ireland, Latvia, Malta, Monaco, Montenegro, Netherlands, North Macedonia, Norway, Poland, Romania, Slovak Republic, Sweden, and United Kingdom), but the largest European States did, as well others not members of the Council, such as Belarus, Benin, Burkina Faso, Côte d'Ivoire, Guinea, Israel, Marocco, and Niger.178 These regional differences suggest that this strategy is not universally perceived as convenient or effective in facing counterfeits.

The FDA currently sponsors a public campaign named “BeSafeRx”, characterized by a specific warning to beware of online pharmacies that: (i) allow to buy drugs without a prescription from the doctor; (ii) offer deep discounts or cheap prices that seem “too good to be true”; (iii) send spam or unsolicited email offering cheap drugs; (iv) are located outside of the United States.179 No data have been published yet on the efficacy of the campaign, but it is to be noted that this strategy addresses only indirectly the issue of the counterfeit drugs.

The Fakeshare is a European project coordinated by the Italian Medicines Agency (AIFA), launched in 2013 and aiming to produce public awareness on the pandemic use of counterfeit medicines in the continent. The project produced a public advertisement translated in the European languages showing the risks of these products, such as a picture of a male (not by chance) mouth with a gun bullet on the tongue ready to swallow illustrating the message “Buying Medicine online: Think you know what you are getting?”.180 Although meritorious, the output and the social redemption of this campaign are not known.

Machine Learning, which has been used with some successes to combat digital opioid access,181 has also been considered among the possible strategies to face the increasing use of social networks, like Facebook, Instagram, and Twitter,2,113 to spread and sell illegal and counterfeit drugs. However, this solution has not been adopted yet to detect, classify, and report illicit online marketing and sales of drugs for sexual medicine.

Additionally, the enactment of telemedicine during COVID-19 has proven that remote consultations are an attractive approach for sexual health, as for many other branches of clinical medicine.182,183 While clinical assessment cannot be fully performed with a video interview, there is no doubt that a remote consultation would be far more beneficial than “asking doctor Google”.184,185

Telemedicine might also be beneficial in the fight against counterfeit medications: the availability of quick, anonymous and possibly cheap remote consultations issued by certified specialists might encourage patients to refrain from self-diagnosis and self-treatment. However, no definite evidence exists at this time of the efficacy of this strategy.

Technological Solutions Against Counterfeit Medications

While social interventions are fundamental to contrast counterfeit drugs, technical solutions may also be crucial and could be helpful to overcome the potential gaps (Figure 3 ). While, as a rule of thumb, it would be wise to refrain from buying drugs online at all, it is not uncommon for people to get PDE5i from peers such as friends and colleagues,136 with little information, if any, on the source of the drug. Several studies performed in the last years have collected the telltale signs of a counterfeit medication: drugs shipped or sold without accompanying leaflets or outer packaging, missing a clear expiration date or information on manufacturing country19,65 are most likely not genuine products. Since pills and tablets are the most likely products to be counterfeited and their form allows for easy storage (once again, increasing the risks of microbial contamination), the product's shape, color and aspect can be selected or modified by the manufacturer to increase similarity to the genuine product. Therefore, several strategies have also been envisioned by pharmaceutical companies to identify a counterfeit product by the external packaging only, including the use of serial numbers, barcodes, holography, radiofrequency identification device, or unreplaceable sealings on the package itself.119 While theoretically able to solve the issue of counterfeit medications, such strategies are not always applicable: as an example, the costs for the radiofrequency identification device method are often excessively high, reaching up to billion dollars for large-chain pharmacies,6,186 and serialization requires several checks by manufacturers, importers, distributors and resellers, with some countries unable to meet the deadline proposed by regulatory agencies. Of course, this is on top of other concerns, such as the issue of patients’ privacy and data security.7 This once again highlights the need of a more comprehensive approach, supported by larger authorities, such as FDA and WHO.

Strategies to fight counterfeit medications.
Figure 3

Strategies to fight counterfeit medications.

From a technical point of view, different analyses on samples are available to researchers having access to a modern laboratory134: several techniques have been successfully used in the last decades to perform assessment of any tablet's contents (Table 1 ). While some chromatography techniques require destruction of the tablet itself, possibly becoming a problem from a legal point of view,14,68 nondestructive techniques, such as near-infrared spectroscopy,14 Raman spectroscopy12 or nuclear magnetic resonance relaxometry,48,132 could be helpful in these regards by leaving the tablet intact. Available techniques also differ for sensitivity, costs, required training and personnel, limiting the possible applications in different settings: therefore, relying upon technical investigations alone in order to identify all counterfeit medications being shipped worldwide is not a feasible strategy.

Table 1

Methods used to investigate quality of counterfeit PDE5i and/or prevalence of contaminants

Method usedReference(s)
Atmospheric solids analysis probe with time-of-flight mass spectrometry (ASAP-TOF-MS)47
Attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy26,4446,103,104
Calorimetry88
Capillary electrophoresis94
Chemometry33
Chiroptical and vibrational spectroscopy67
Chromatography5,77
Desorption electrospray ionization (DESI) mass spectrometry93
Differential scanning calorimetry (DSC)19
Dissolution test36,91
Dynamic thermal analysis78
Fourier-transform infrared spectroscopy (FTIR)14,19
Gas chromatography–mass spectrometry (GC-MS)23,6266,98
High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD)–GC-MS97
High-performance liquid chromatography (HPLC)5356
HPLC - mass spectrometry (HPLC-MS)85,86
HPLC - tandem mass spectrometry (HPLC-MS/MS)57,144
HPLC - diode array detector (HPLC-DAD)26
HPLC - diode array detector - quadrupole-time-of-flight mass analyzer (HPLC-DAD-QTOF-MS)43
HPLC - photo diode array (HPLC-PDA)15,85-87
HPLC - quadrupole-time-of-flight mass analyzer (HPLC-QTOF)76
HPLC - ultraviolet detection (HPLC-UV)58-61,102
HPLC - charged aerosol detector (HPLC-CAD)84
High-performance thin layer chromatography (HP-TLC)83
Hyperspectral imaging techniques96
Infrared spectroscopy (IR)14,18,25,55,90
Instrumental neutron activation analysis (INAA)41,42
Ion beam analysis (IBA)42
Laser desorption/Ionization89
Liquid chromatography (LC)89
LC - quadrupole-time of flight mass spectrometry (LC-QTOF-MS)82
LC - quadrupole-time of flight tandem mass spectrometry (LC-QTOF-MS/MS)38,7982
LC - charged aerosol detector (LC-CAD)75
LC - diode array detector (LC-DAD)75
LC - diode array detector and mass spectrometry (LC-DAD-MS)49
LC - diode array detector and tandem mass spectrometry (LC-DAD-MS/MS)50
LC - mass spectrometry (LC-MS)18,33,41,65,7375
LC - tandem mass spectrometry (LC-MS/MS)66,70-72,101
Mass spectrometry (MS)15
Melting26
Microbial analysis69
Microtomography68
Multicollector inductively coupled plasma mass spectrometry (MC-ICPMS)52
Near infrared (NIR) spectroscopy14,35,36,4951
Nuclear magnetic resonance (RMN) relaxometry48
Nuclear magnetic resonance (RMN) spectroscopy13,26,33,3740
Paper spray ionization (PSI) – Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS)105
Physical profiling25,103
Raman spectroscopy1214,17,18,20,26-28,3436
Spectrophotometry95
Tandem mass spectrometry (MS/MS)24
Thermo-gravimetry (TG)19
Ultra-performance liquid chromatography (U-HPLC)32,100
Ultra-performance liquid chromatography - high resolution tandem mass spectrometry (U-HPLC‒HRMS/MS)29,30
Ultra-performance liquid chromatography - mass spectrometry (U-HPLC-MS)22
Ultra-performance liquid chromatography - ultra violet detection (UHPLC-UV)16
Ultra-performance liquid chromatography hybrid-ion trap-Orbitrap mass spectrometry (UHPLC-Orbitrap-MS/MS)26
Ultra-performance liquid chromatography quadrupole-time of flight tandem mass spectrometry (UPLC-QTOF-MS/MS)26
Ultra-performance liquid chromatography-time-of-flight mass spectrometry (UHPLC/Q-TOF-MS)23
Ultraviolet spectroscopy18
Ultraviolet–visible spectroscopy (UV-VIS)33
Visual inspection19
Volume holograms99
X-ray diffractometry11,15
X-ray fluorescence (XRF) spectrometry21,31
Method usedReference(s)
Atmospheric solids analysis probe with time-of-flight mass spectrometry (ASAP-TOF-MS)47
Attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy26,4446,103,104
Calorimetry88
Capillary electrophoresis94
Chemometry33
Chiroptical and vibrational spectroscopy67
Chromatography5,77
Desorption electrospray ionization (DESI) mass spectrometry93
Differential scanning calorimetry (DSC)19
Dissolution test36,91
Dynamic thermal analysis78
Fourier-transform infrared spectroscopy (FTIR)14,19
Gas chromatography–mass spectrometry (GC-MS)23,6266,98
High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD)–GC-MS97
High-performance liquid chromatography (HPLC)5356
HPLC - mass spectrometry (HPLC-MS)85,86
HPLC - tandem mass spectrometry (HPLC-MS/MS)57,144
HPLC - diode array detector (HPLC-DAD)26
HPLC - diode array detector - quadrupole-time-of-flight mass analyzer (HPLC-DAD-QTOF-MS)43
HPLC - photo diode array (HPLC-PDA)15,85-87
HPLC - quadrupole-time-of-flight mass analyzer (HPLC-QTOF)76
HPLC - ultraviolet detection (HPLC-UV)58-61,102
HPLC - charged aerosol detector (HPLC-CAD)84
High-performance thin layer chromatography (HP-TLC)83
Hyperspectral imaging techniques96
Infrared spectroscopy (IR)14,18,25,55,90
Instrumental neutron activation analysis (INAA)41,42
Ion beam analysis (IBA)42
Laser desorption/Ionization89
Liquid chromatography (LC)89
LC - quadrupole-time of flight mass spectrometry (LC-QTOF-MS)82
LC - quadrupole-time of flight tandem mass spectrometry (LC-QTOF-MS/MS)38,7982
LC - charged aerosol detector (LC-CAD)75
LC - diode array detector (LC-DAD)75
LC - diode array detector and mass spectrometry (LC-DAD-MS)49
LC - diode array detector and tandem mass spectrometry (LC-DAD-MS/MS)50
LC - mass spectrometry (LC-MS)18,33,41,65,7375
LC - tandem mass spectrometry (LC-MS/MS)66,70-72,101
Mass spectrometry (MS)15
Melting26
Microbial analysis69
Microtomography68
Multicollector inductively coupled plasma mass spectrometry (MC-ICPMS)52
Near infrared (NIR) spectroscopy14,35,36,4951
Nuclear magnetic resonance (RMN) relaxometry48
Nuclear magnetic resonance (RMN) spectroscopy13,26,33,3740
Paper spray ionization (PSI) – Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS)105
Physical profiling25,103
Raman spectroscopy1214,17,18,20,26-28,3436
Spectrophotometry95
Tandem mass spectrometry (MS/MS)24
Thermo-gravimetry (TG)19
Ultra-performance liquid chromatography (U-HPLC)32,100
Ultra-performance liquid chromatography - high resolution tandem mass spectrometry (U-HPLC‒HRMS/MS)29,30
Ultra-performance liquid chromatography - mass spectrometry (U-HPLC-MS)22
Ultra-performance liquid chromatography - ultra violet detection (UHPLC-UV)16
Ultra-performance liquid chromatography hybrid-ion trap-Orbitrap mass spectrometry (UHPLC-Orbitrap-MS/MS)26
Ultra-performance liquid chromatography quadrupole-time of flight tandem mass spectrometry (UPLC-QTOF-MS/MS)26
Ultra-performance liquid chromatography-time-of-flight mass spectrometry (UHPLC/Q-TOF-MS)23
Ultraviolet spectroscopy18
Ultraviolet–visible spectroscopy (UV-VIS)33
Visual inspection19
Volume holograms99
X-ray diffractometry11,15
X-ray fluorescence (XRF) spectrometry21,31
Table 1

Methods used to investigate quality of counterfeit PDE5i and/or prevalence of contaminants

Method usedReference(s)
Atmospheric solids analysis probe with time-of-flight mass spectrometry (ASAP-TOF-MS)47
Attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy26,4446,103,104
Calorimetry88
Capillary electrophoresis94
Chemometry33
Chiroptical and vibrational spectroscopy67
Chromatography5,77
Desorption electrospray ionization (DESI) mass spectrometry93
Differential scanning calorimetry (DSC)19
Dissolution test36,91
Dynamic thermal analysis78
Fourier-transform infrared spectroscopy (FTIR)14,19
Gas chromatography–mass spectrometry (GC-MS)23,6266,98
High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD)–GC-MS97
High-performance liquid chromatography (HPLC)5356
HPLC - mass spectrometry (HPLC-MS)85,86
HPLC - tandem mass spectrometry (HPLC-MS/MS)57,144
HPLC - diode array detector (HPLC-DAD)26
HPLC - diode array detector - quadrupole-time-of-flight mass analyzer (HPLC-DAD-QTOF-MS)43
HPLC - photo diode array (HPLC-PDA)15,85-87
HPLC - quadrupole-time-of-flight mass analyzer (HPLC-QTOF)76
HPLC - ultraviolet detection (HPLC-UV)58-61,102
HPLC - charged aerosol detector (HPLC-CAD)84
High-performance thin layer chromatography (HP-TLC)83
Hyperspectral imaging techniques96
Infrared spectroscopy (IR)14,18,25,55,90
Instrumental neutron activation analysis (INAA)41,42
Ion beam analysis (IBA)42
Laser desorption/Ionization89
Liquid chromatography (LC)89
LC - quadrupole-time of flight mass spectrometry (LC-QTOF-MS)82
LC - quadrupole-time of flight tandem mass spectrometry (LC-QTOF-MS/MS)38,7982
LC - charged aerosol detector (LC-CAD)75
LC - diode array detector (LC-DAD)75
LC - diode array detector and mass spectrometry (LC-DAD-MS)49
LC - diode array detector and tandem mass spectrometry (LC-DAD-MS/MS)50
LC - mass spectrometry (LC-MS)18,33,41,65,7375
LC - tandem mass spectrometry (LC-MS/MS)66,70-72,101
Mass spectrometry (MS)15
Melting26
Microbial analysis69
Microtomography68
Multicollector inductively coupled plasma mass spectrometry (MC-ICPMS)52
Near infrared (NIR) spectroscopy14,35,36,4951
Nuclear magnetic resonance (RMN) relaxometry48
Nuclear magnetic resonance (RMN) spectroscopy13,26,33,3740
Paper spray ionization (PSI) – Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS)105
Physical profiling25,103
Raman spectroscopy1214,17,18,20,26-28,3436
Spectrophotometry95
Tandem mass spectrometry (MS/MS)24
Thermo-gravimetry (TG)19
Ultra-performance liquid chromatography (U-HPLC)32,100
Ultra-performance liquid chromatography - high resolution tandem mass spectrometry (U-HPLC‒HRMS/MS)29,30
Ultra-performance liquid chromatography - mass spectrometry (U-HPLC-MS)22
Ultra-performance liquid chromatography - ultra violet detection (UHPLC-UV)16
Ultra-performance liquid chromatography hybrid-ion trap-Orbitrap mass spectrometry (UHPLC-Orbitrap-MS/MS)26
Ultra-performance liquid chromatography quadrupole-time of flight tandem mass spectrometry (UPLC-QTOF-MS/MS)26
Ultra-performance liquid chromatography-time-of-flight mass spectrometry (UHPLC/Q-TOF-MS)23
Ultraviolet spectroscopy18
Ultraviolet–visible spectroscopy (UV-VIS)33
Visual inspection19
Volume holograms99
X-ray diffractometry11,15
X-ray fluorescence (XRF) spectrometry21,31
Method usedReference(s)
Atmospheric solids analysis probe with time-of-flight mass spectrometry (ASAP-TOF-MS)47
Attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy26,4446,103,104
Calorimetry88
Capillary electrophoresis94
Chemometry33
Chiroptical and vibrational spectroscopy67
Chromatography5,77
Desorption electrospray ionization (DESI) mass spectrometry93
Differential scanning calorimetry (DSC)19
Dissolution test36,91
Dynamic thermal analysis78
Fourier-transform infrared spectroscopy (FTIR)14,19
Gas chromatography–mass spectrometry (GC-MS)23,6266,98
High performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD)–GC-MS97
High-performance liquid chromatography (HPLC)5356
HPLC - mass spectrometry (HPLC-MS)85,86
HPLC - tandem mass spectrometry (HPLC-MS/MS)57,144
HPLC - diode array detector (HPLC-DAD)26
HPLC - diode array detector - quadrupole-time-of-flight mass analyzer (HPLC-DAD-QTOF-MS)43
HPLC - photo diode array (HPLC-PDA)15,85-87
HPLC - quadrupole-time-of-flight mass analyzer (HPLC-QTOF)76
HPLC - ultraviolet detection (HPLC-UV)58-61,102
HPLC - charged aerosol detector (HPLC-CAD)84
High-performance thin layer chromatography (HP-TLC)83
Hyperspectral imaging techniques96
Infrared spectroscopy (IR)14,18,25,55,90
Instrumental neutron activation analysis (INAA)41,42
Ion beam analysis (IBA)42
Laser desorption/Ionization89
Liquid chromatography (LC)89
LC - quadrupole-time of flight mass spectrometry (LC-QTOF-MS)82
LC - quadrupole-time of flight tandem mass spectrometry (LC-QTOF-MS/MS)38,7982
LC - charged aerosol detector (LC-CAD)75
LC - diode array detector (LC-DAD)75
LC - diode array detector and mass spectrometry (LC-DAD-MS)49
LC - diode array detector and tandem mass spectrometry (LC-DAD-MS/MS)50
LC - mass spectrometry (LC-MS)18,33,41,65,7375
LC - tandem mass spectrometry (LC-MS/MS)66,70-72,101
Mass spectrometry (MS)15
Melting26
Microbial analysis69
Microtomography68
Multicollector inductively coupled plasma mass spectrometry (MC-ICPMS)52
Near infrared (NIR) spectroscopy14,35,36,4951
Nuclear magnetic resonance (RMN) relaxometry48
Nuclear magnetic resonance (RMN) spectroscopy13,26,33,3740
Paper spray ionization (PSI) – Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS)105
Physical profiling25,103
Raman spectroscopy1214,17,18,20,26-28,3436
Spectrophotometry95
Tandem mass spectrometry (MS/MS)24
Thermo-gravimetry (TG)19
Ultra-performance liquid chromatography (U-HPLC)32,100
Ultra-performance liquid chromatography - high resolution tandem mass spectrometry (U-HPLC‒HRMS/MS)29,30
Ultra-performance liquid chromatography - mass spectrometry (U-HPLC-MS)22
Ultra-performance liquid chromatography - ultra violet detection (UHPLC-UV)16
Ultra-performance liquid chromatography hybrid-ion trap-Orbitrap mass spectrometry (UHPLC-Orbitrap-MS/MS)26
Ultra-performance liquid chromatography quadrupole-time of flight tandem mass spectrometry (UPLC-QTOF-MS/MS)26
Ultra-performance liquid chromatography-time-of-flight mass spectrometry (UHPLC/Q-TOF-MS)23
Ultraviolet spectroscopy18
Ultraviolet–visible spectroscopy (UV-VIS)33
Visual inspection19
Volume holograms99
X-ray diffractometry11,15
X-ray fluorescence (XRF) spectrometry21,31

Last, but not least, among the possible pharmaceutical forms of the PDE5i, the orodispersible one seems particularly interesting for its pharmacokinetic characteristics.187 In particular, the sildenafil orodispersible film (SODF), based on hydrophilic polymers with drug and other excipients, expresses the unique and peculiar ability to preserve the male intimacy through a convenient and discrete dosage form.188 Differently from the other pharmaceutical formulations of the products belonging from the same class of drugs, being not easily recognized as a drug, the SODF could be classified as an “intimacy-sparing” PDE5i. Moreover, SODF does not require the intake of a liquid, hence reducing the anxiety of the patient and the stigma of assuming a well recognizable drug to address ED, while the large surface area leads to rapid disintegration in the mouth.188

A very interesting add on is the fact that the SODF appear as the unique PDE5i virtually exempt from the risk of counterfeiting.189,190 On top of the still valid patents for ODF,191,192 production of such formulations require, in fact, several expensive steps needing highly specialized laboratories and materials131 (ie, IBSA ODF): as an example, the hygroscopic nature of the support and of the drug require special precautions during production, and excessively long exposure before individual packaging could damage the quality and efficacy of the drug.189 In fact, the performance of SODF is dependent on manufacturing processes that maximize the porous structure of the tablet matrix, incorporating a disintegrating agent, and the use of highly water-soluble excipients to allow quick ingress of water, finally facilitating rapid oral disintegration193; all technical aspects which are tremendously hard to be replicated in the black-market setting. Therefore, on top of the already demonstrated safety and efficacy,187,194196 the reliability and reduced risk of counterfeiting are additional added benefits of the SODF formulation.

Strengths and Limitations

In this review, we systematically reviewed currently available literature concerning the use of counterfeit PDE5i, highlighting several topics relevant for sexual medicine experts as well as for the general population. To our best knowledge, this is the first time that this topic has been addressed systematically, highlighting all known risks for individual and public health as well as pointing out available strategies aimed to contain the counterfeit phenomenon, and reasons for their partial success. The present paper, however, has some limitations, mostly inherent to the available literature being investigated – such as the lack of any clear rate of counterfeit medication use and the presence of a limited amount of clinical studies.

Conclusion

While generally under-reported, counterfeit medications are a tangible issue requiring intervention, due to the potential risks for healthcare. This becomes of paramount importance in the context of sexual medicine, being pro-erectile drugs the most counterfeited products in several countries. As reported in different guidelines,117,138142 PDE5i are safe and effective if appropriately used; however, several risks and complications might arise following use of counterfeit medications. Microbial contamination, inadequate dosing of the active pharmaceutical ingredients and adulteration with other drugs or toxic compounds can both have direct effects on the consumers’ health; additionally, unsupervised use results in decreased awareness of the underlying risk factors, increasing the potential burden for healthcare. Such costs should also consider the reduced reinvestments on R&D by medical companies, as well as the potential costs for public health from inadequate treatment and side effects of contaminants. While technologies to detect counterfeit are increasingly available, political aspects and the costs and required expertise limit their application. Within the various pharmaceutical formulations, the ODF is the less likely to be prone to be counterfeited and warrants a unique originality of its content, dosage, and safety. Physicians treating sexual dysfunctions and pharmacists should inform their patients and clients about the issues of counterfeit medical products, as well as suggest refraining from buying drugs online and taking tablets of dubious origin from peers.

Statement of Authorship

Andrea Sansone, Emmanuele A. Jannini: Conceptualization; Andrea Sansone, Emmanuele A. Jannini: Methodology; Andrea Sansone: Investigation; Andrea Sansone: Writing – Original Draft; Andrea Sansone,Béatrice Cuzin, Emmanuele A. Jannini: Writing – Review & Editing; Emmanuele A. Jannini: Funding Acquisition; Emmanuele A. Jannini: Resources; Emmanuele A. Jannini: Supervision.

Funding: This review was funded by IBSA International (Lugano, Switzerland).

References

1

Yafi
FA
,
Jenkins
L
,
Albersen
M
et al.
Erectile dysfunction
.
Nat Rev Dis Primers
2016
;
2
:
16003
.

2

Sansone
A
,
Cignarelli
A
,
Ciocca
G
et al.
The sentiment analysis of tweets as a new tool to measure public perception of male erectile and ejaculatory dysfunctions
.
Sex Med
2019
;
7
:
464
-
471
.

3

Corona
G
,
Maggi
M
,
Jannini
EA.
EDEUS, a real-life study on the users of phosphodiesterase type 5 inhibitors: Prevalence, perceptions, and health care-seeking behavior among European men with a focus on 2nd-generation avanafil
.
Sex Med
2018
;
6
:
15
-
23
.

4

World Health Organization. WHO global surveillance and monitoring system. 2017. Available at:
 https://www.who.int/medicines/regulation/ssffc/publications/gsms-report-sf/en/. Accessed April 9, 2021.

5

Deconinck
E
,
Sacre
PY
,
Courselle
P
et al.
Chemometrics and chromatographic fingerprints to discriminate and classify counterfeit medicines containing PDE-5 inhibitors
.
Talanta
2012
;
100
:
123
-
133
.

6

Chiang
J
,
Yafi
FA
,
Dorsey
PJ
Jr.
et al.
The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction
.
Transl Androl Urol
2017
;
6
:
12
-
19
.

7

Jack
A.
Counterfeit medicines. Bitter pills
.
BMJ
2007
;
335
:
1120
-
1121
.

8

Jackson
G
,
Arver
S
,
Banks
I
et al.
Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
.
Int J Clin Pract
2010
;
64
:
497
-
504
.

9

Glass
BD.
Counterfeit drugs and medical devices in developing countries
.
Res Rep Trop Med
2014
;
5
:
11
-
22
.

10

Munn
Z
,
Peters
MDJ
,
Stern
C
et al.
Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach
.
BMC Med Res Methodol
2018
;
18
:
143
.

11

Maurin
JK
,
Plucinski
F
,
Mazurek
AP
et al.
The usefulness of simple X-ray powder diffraction analysis for counterfeit control–The viagra example
.
J Pharm Biomed Anal
2007
;
43
:
1514
-
1518
.

12

de Veij
M
,
Deneckere
A
,
Vandenabeele
P
et al.
Detection of counterfeit viagra with Raman spectroscopy
.
J Pharm Biomed Anal
2008
;
46
:
303
-
309
.

13

Trefi
S
,
Routaboul
C
,
Hamieh
S
et al.
Analysis of illegally manufactured formulations of tadalafil (Cialis) by 1H NMR, 2D DOSY 1H NMR and Raman spectroscopy
.
J Pharm Biomed Anal
2008
;
47
:
103
-
113
.

14

Sacre
PY
,
Deconinck
E
,
De Beer
T
et al.
Comparison and combination of spectroscopic techniques for the detection of counterfeit medicines
.
J Pharm Biomed Anal
2010
;
53
:
445
-
453
.

15

Newton
PN
,
Green
MD
,
Mildenhall
DC
et al.
Poor quality vital anti-malarials in Africa - An urgent neglected public health priority
.
Malar J
2011
;
10
:
352
.

16

Sacre
PY
,
Deconinck
E
,
Chiap
P
et al.
Development and validation of a ultra-high-performance liquid chromatography-UV method for the detection and quantification of erectile dysfunction drugs and some of their analogues found in counterfeit medicines
.
J Chromatogr A
2011
;
1218
:
6439
-
6447
.

17

Sacre
PY
,
Deconinck
E
,
Saerens
L
et al.
Detection of counterfeit Viagra(R) by Raman microspectroscopy imaging and multivariate analysis
.
J Pharm Biomed Anal
2011
;
56
:
454
-
461
.

18

Campbell
N
,
Clark
JP
,
Stecher
VJ
et al.
Internet-ordered viagra (sildenafil citrate) is rarely genuine
.
J Sex Med
2012
;
9
:
2943
-
2951
.

19

Gaudiano
MC
,
Manna
L
,
Rodomonte
AL
et al.
A survey on illegal and counterfeit medicines for the treatment of erectile dysfunctions in Italy
.
J Sex Med
2012
;
9
:
2130
-
2137
.

20

Kwok
K
,
Taylor
LS.
Analysis of counterfeit Cialis(R) tablets using Raman microscopy and multivariate curve resolution
.
J Pharm Biomed Anal
2012
;
66
:
126
-
135
.

21

Ortiz
RS
,
Mariotti
KC
,
Schwab
NV
et al.
Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry
.
J Pharm Biomed Anal
2012
;
58
:
7
-
11
.

22

Ortiz
RS
,
Mariotti Kde
C
,
Holzschuh
MH
et al.
Profiling counterfeit cialis, viagra and analogs by UPLC-MS
.
Forensic Sci Int
2013
;
229
:
13
-
20
.

23

Damiano
F
,
Silva
C
,
Gregori
A
et al.
Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS
.
Sci Justice
2014
;
54
:
228
-
237
.

24

Mustazza
C
,
Borioni
A
,
Rodomonte
AL
et al.
Characterization of Sildenafil analogs by MS/MS and NMR: A guidance for detection and structure elucidation of phosphodiesterase-5 inhibitors
.
J Pharm Biomed Anal
2014
;
96
:
170
-
186
.

25

Custers
D
,
Vandemoortele
S
,
Bothy
JL
et al.
Physical profiling and IR spectroscopy: simple and effective methods to discriminate between genuine and counterfeit samples of Viagra(R) and Cialis(R)
.
Drug Test Anal
2016
;
8
:
378
-
387
.

26

Keizers
PHJ
,
Wiegard
A
,
Venhuis
BJ.
The quality of sildenafil active substance of illegal source
.
J Pharm Biomed Anal
2016
;
131
:
133
-
139
.

27

Lanzarotta
A
,
Lorenz
L
,
Batson
JS
et al.
Development and implementation of a pass/fail field-friendly method for detecting sildenafil in suspect pharmaceutical tablets using a handheld Raman spectrometer and silver colloids
.
J Pharm Biomed Anal
2017
;
146
:
420
-
425
.

28

Rebiere
H
,
Martin
M
,
Ghyselinck
C
et al.
Raman chemical imaging for spectroscopic screening and direct quantification of falsified drugs
.
J Pharm Biomed Anal
2018
;
148
:
316
-
323
.

29

Jiru
M
,
Stranska-Zachariasova
M
,
Dzuman
Z
et al.
Analysis of phosphodiesterase type 5 inhibitors as possible adulterants of botanical-based dietary supplements: Extensive survey of preparations available at the Czech market
.
J Pharm Biomed Anal
2019
;
164
:
713
-
724
.

30

Lee
JH
,
Park
HN
,
Park
S
et al.
Development of a specific fragment pattern-based quadrupole-Orbitrap mass spectrometry method to screen adulterated products of phosphodiesterase-5 inhibitors and their analogues
.
Sci Justice
2019
;
59
:
433
-
441
.

31

Soares
F
,
Anzanello
MJ
,
Fogliatto
FS
et al.
Enhancing counterfeit and illicit medicines grouping via feature selection and X-ray fluorescence spectrometry
.
J Pharm Biomed Anal
2019
;
174
:
198
-
205
.

32

Benchekroun
YH
,
El Karbane
M
,
Ihssane
B
et al.
Application of design space, uncertainty, and risk profile strategies to the development and validation of UPLC method for the characterization of four authorized phosphodiesterase type 5 inhibitors to combat counterfeit drugs
.
J AOAC Int
2020
;
103
:
715
-
724
.

33

Keizers
PHJ
,
Bakker
F
,
Ferreira
J
et al.
Benchtop NMR spectroscopy in the analysis of substandard and falsified medicines as well as illegal drugs
.
J Pharm Biomed Anal
2020
;
178
:
112939

34

Sanada
T
,
Yoshida
N
,
Kimura
K
et al.
Discrimination of falsified erectile dysfunction medicines by use of an ultra-compact Raman scattering spectrometer
.
Pharmacy (Basel)
2020
;
9
:
3
.

35

Sanada
T
,
Yoshida
N
,
Matsushita
R
et al.
Falsified tadalafil tablets distributed in Japan via the internet
.
Forensic Sci Int
2020
;
307
:
110143

36

Zhu
S
,
Yoshida
N
,
Kimura
K
et al.
Falsified vardenafil tablets available online
.
J Pharm Biomed Anal
2020
;
177
:
112872

37

Holzgrabe
U
,
Malet-Martino
M.
Analytical challenges in drug counterfeiting and falsification-The NMR approach
.
J Pharm Biomed Anal
2011
;
55
:
679
-
687
.

38

Johansson
M
,
Fransson
D
,
Rundlof
T
et al.
A general analytical platform and strategy in search for illegal drugs
.
J Pharm Biomed Anal
2014
;
100
:
215
-
229
.

39

Ribeiro
MVM
,
Boralle
N
,
Felippe
LG
et al.
(1)H NMR determination of adulteration of anabolic steroids in seized drugs
.
Steroids
2018
;
138
:
47
-
56
.

40

Trefi
S
,
Gilard
V
,
Balayssac
S
et al.
The usefulness of 2D DOSY and 3D DOSY-COSY 1H NMR for mixture analysis: Application to genuine and fake formulations of sildenafil (Viagra)
.
Magn Reson Chem
2009
;
47
:
Suppl 1
:
S163
-
S173
.

41

Romolo
FS
,
Salvini
A
,
Zelaschi
F
et al.
Instrumental neutron activation analysis (INAA) and liquid chromatography (LC) coupled to high resolution mass spectrometry (HRMS) characterisation of sildenafil based products seized on the Italian illegal market
.
Forensic Sci Int
2019
;
1
:
126
-
136
.

42

Romolo
FS
,
Sarilar
M
,
Antoine
J
et al.
Ion beam analysis (IBA) and instrumental neutron activation analysis (INAA) for forensic characterisation of authentic Viagra(R) and of sildenafil-based illegal products
.
Talanta
2021
;
224
:
121829

43

Bortolini
C
,
Pivato
A
,
Bogialli
S
et al.
"One-shot" analysis of PDE-5 inhibitors and analogues in counterfeit herbal natural products using an LC-DAD-QTOF system
.
Anal Bioanal Chem
2015
;
407
:
6207
-
6216
.

44

Anzanello
MJ
,
Yamashita
G
,
Marcelo
M
et al.
A genetic algorithm-based framework for wavelength selection on sample categorization
.
Drug Test Anal
2017
;
9
:
1172
-
1181
.

45

Coelho Neto
J
,
Lisboa
FLC
ATR-FTIR characterization of generic brand-named and counterfeit sildenafil- and tadalafil-based tablets found on the Brazilian market
.
Sci Justice
2017
;
57
:
283
-
295
.

46

Kahmann
A
,
Anzanello
MJ
,
Fogliatto
FS
et al.
Interval importance index to select relevant ATR-FTIR wavenumber intervals for falsified drug classification
.
J Pharm Biomed Anal
2018
;
158
:
494
-
503
.

47

Twohig
M
,
Skilton
SJ
,
Fujimoto
G
et al.
Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe
.
Drug Test Anal
2010
;
2
:
45
-
50
.

48

Wilczynki
S
,
Petelenz
M
,
Florek-Wojciechowska
M
et al.
Verification of the authenticity of drugs by means of NMR relaxometry-Viagra((R)) as an example
.
J Pharm Biomed Anal
2017
;
135
:
199
-
205
.

49

Venhuis
BJ
,
Zomer
G
,
Vredenbregt
MJ
et al.
The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis and the optical purity of tadalafil stereoisomers
.
J Pharm Biomed Anal
2010
;
51
:
723
-
727
.

50

Venhuis
BJ
,
Zwaagstra
ME
,
Keizers
PH
et al.
Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments
.
J Pharm Biomed Anal
2014
;
89
:
158
-
165
.

51

Vredenbregt
MJ
,
Blok-Tip
L
,
Hoogerbrugge
R
et al.
Screening suspected counterfeit Viagra and imitations of Viagra with near-infrared spectroscopy
.
J Pharm Biomed Anal
2006
;
40
:
840
-
849
.

52

Clough
R
,
Evans
P
,
Catterick
T
et al.
Delta34S measurements of sulfur by multicollector inductively coupled plasma mass spectrometry
.
Anal Chem
2006
;
78
:
6126
-
6132
.

53

Chaubey
SK
,
Sangla
KS
,
Suthaharan
EN
et al.
Severe hypoglycaemia associated with ingesting counterfeit medication
.
Med J Aust
2010
;
192
:
716
-
717
.

54

Fidan
AK
,
Bakirdere
S.
Simultaneous determination of sildenafil and tadalafil in legal drugs, illicit/counterfeit drugs, and wastewater samples by high-performance liquid chromatography
.
J AOAC Int
2016
;
99
:
923
-
928
.

55

Taher
A
,
Setiawati
A.
VICTORY project: A study of counterfeit PDE5 inhibitor (sildenafil) in Indonesia
.
Acta Med Indones
2013
;
45
:
290
-
294
.

56

Tomic
S
,
Milcic
N
,
Sokolic
M
et al.
Identification of counterfeit medicines for erectile dysfunction from an illegal supply chain
.
Arh Hig Rada Toksikol
2010
;
61
:
69
-
75
.

57

Dean
J
,
Klep
R
,
Aquilina
JW.
Counterfeit dapoxetine sold on the internet contains undisclosed sildenafil
.
Int J Clin Pract
2010
;
64
:
1319
-
1322
.

58

Fejos
I
,
Neumajer
G
,
Beni
S
et al.
Qualitative and quantitative analysis of PDE-5 inhibitors in counterfeit medicines and dietary supplements by HPLC-UV using sildenafil as a sole reference
.
J Pharm Biomed Anal
2014
;
98
:
327
-
333
.

59

Park
M
,
Ahn
S.
Quantitative analysis of sildenafil and tadalafil in various fake drugs recently distributed in Korea
.
J Forensic Sci
2012
;
57
:
1637
-
1640
.

60

Sacre
PY
,
Deconinck
E
,
Daszykowski
M
et al.
Impurity fingerprints for the identification of counterfeit medicines–A feasibility study
.
Anal Chim Acta
2011
;
701
:
224
-
231
.

61

Yoshida
N
,
Khan
MH
,
Tabata
H
et al.
A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010
.
BMC Pharmacol Toxicol
2014
;
15
:
13
.

62

Custers
D
,
Canfyn
M
,
Courselle
P
et al.
Headspace-gas chromatographic fingerprints to discriminate and classify counterfeit medicines
.
Talanta
2014
;
123
:
78
-
88
.

63

Deconinck
E
,
Canfyn
M
,
Sacre
PY
et al.
Evaluation of the residual solvent content of counterfeit tablets and capsules
.
J Pharm Biomed Anal
2013
;
81-82
:
80
-
88
.

64

Lee
W
,
Kim
HJ
,
Lee
ME
et al.
Reliable screening and classification of phosphodiesterase type 5 inhibitors in dietary supplements using gas chromatography /mass spectrometry combined with specific common ions
.
J Chromatogr A
2020
;
1623
:
461210

65

Odoardi
S
,
Mestria
S
,
Biosa
G
et al.
An overview on performance and image enhancing drugs (PIEDs) confiscated in Italy in the period 2017-2019
.
Clin Toxicol (Phila)
2021
;
59
:
47
-
52
.

66

Thevis
M
,
Schrader
Y
,
Thomas
A
et al.
Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches
.
J Anal Toxicol
2008
;
32
:
232
-
240
.

67

Kralik
F
,
Jirmasek
P
,
Kuchar
M
et al.
Chiroptical and vibrational spectroscopic study of genuine and counterfeit medicines containing tadalafil
.
Chirality
2018
;
30
:
560
-
567
.

68

Wilczynski
S
,
Koprowski
R
,
Stolecka-Warzecha
A
et al.
The use of microtomographic imaging in the identification of counterfeit medicines
.
Talanta
2019
;
195
:
870
-
875
.

69

Pullirsch
D
,
Bellemare
J
,
Hackl
A
et al.
Microbiological contamination in counterfeit and unapproved drugs
.
BMC Pharmacol Toxicol
2014
;
15
:
34
.

70

Causanilles
A
,
Rojas Cantillano
D
,
Emke
E
et al.
Comparison of phosphodiesterase type V inhibitors use in eight European cities through analysis of urban wastewater
.
Environ Int
2018
;
115
:
279
-
284
.

71

Lee
JH
,
Park
HN
,
Park
OR
et al.
Screening of illegal sexual enhancement supplements and counterfeit drugs sold in the online and offline markets between 2014 and 2017
.
Forensic Sci Int
2019
;
298
:
10
-
19
.

72

Venhuis
BJ
,
de Voogt
P
,
Emke
E
et al.
Success of rogue online pharmacies: Sewage study of sildenafil in the Netherlands
.
BMJ
2014
;
349
:
g4317
.

73

Deconinck
E
,
Vanhee
C
,
Keizers
P
et al.
The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study
.
Drug Test Anal
2021
;
13
:
833
-
840
.

74

Lebel
P
,
Gagnon
J
,
Furtos
A
et al.
A rapid, quantitative liquid chromatography-mass spectrometry screening method for 71 active and 11 natural erectile dysfunction ingredients present in potentially adulterated or counterfeit products
.
J Chromatogr A
2014
;
1343
:
143
-
151
.

75

Poplawska
M
,
Blazewicz
A
,
Zolek
P
et al.
Determination of flibanserin and tadalafil in supplements for women sexual desire enhancement using high-performance liquid chromatography with tandem mass spectrometer, diode array detector and charged aerosol detector
.
J Pharm Biomed Anal
2014
;
94
:
45
-
53
.

76

Campbell
N
,
Clark
JP
,
Stecher
VJ
et al.
Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors
.
J Sex Med
2013
;
10
:
1842
-
1849
.

77

Krakowska
B
,
Custers
D
,
Deconinck
E
et al.
The Monte Carlo validation framework for the discriminant partial least squares model extended with variable selection methods applied to authenticity studies of Viagra(R) based on chromatographic impurity profiles
.
Analyst
2016
;
141
:
1060
-
1070
.

78

Wilczynski
S.
The use of dynamic thermal analysis to distinguish between genuine and counterfeit drugs
.
Int J Pharm
2015
;
490
:
16
-
21
.

79

Heo
D
,
Kang
JS
,
Choe
S
et al.
Metabolic study of vardenafil analogues: Pseudovardenafil and hydroxyvardenafil
.
J Chromatogr B Analyt Technol Biomed Life Sci
2020
;
1139
:
121940

80

Lee
S
,
Ji
D
,
Park
M
et al.
Development of a comprehensive spectral library of sildenafil and related active analogues using LC-QTOF-MS and its application for screening counterfeit pharmaceuticals
.
Forensic Sci Int
2015
;
257
:
182
-
188
.

81

Ozturk Er
E
,
Ozbek
B
,
Bakirdere
S
Accurate and sensitive determination of sildenafil, tadalafil, vardenafil, and avanafil in illicit erectile dysfunction medications and human urine by LC with quadrupole-TOF-MS/MS and their behaviors in simulated gastric conditions
.
J Sep Sci
2019
;
42
:
475
-
483
.

82

Yeo
M
,
Park
Y
,
Lee
H
et al.
New metabolites of hongdenafil, homosildenafil and hydroxyhomosildenafil
.
J Pharm Biomed Anal
2018
;
149
:
586
-
590
.

83

Do
TT
,
Theocharis
G
,
Reich
E.
Simultaneous detection of three phosphodiesterase type 5 inhibitors and eight of their analogs in lifestyle products and screening for adulterants by high-performance thin-layer chromatography
.
J AOAC Int
2015
;
98
:
1226
-
1233
.

84

Poplawska
M
,
Blazewicz
A
,
Bukowinska
K
et al.
Application of high-performance liquid chromatography with charged aerosol detection for universal quantitation of undeclared phosphodiesterase-5 inhibitors in herbal dietary supplements
.
J Pharm Biomed Anal
2013
;
84
:
232
-
243
.

85

Custers
D
,
Krakowska
B
,
De Beer
JO
et al.
Testing of complementarity of PDA and MS detectors using chromatographic fingerprinting of genuine and counterfeit samples containing sildenafil citrate
.
Anal Bioanal Chem
2016
;
408
:
1643
-
1656
.

86

Custers
D
,
Krakowska
B
,
De Beer
JO
et al.
Chromatographic impurity fingerprinting of genuine and counterfeit Cialis(R) as a means to compare the discriminating ability of PDA and MS detection
.
Talanta
2016
;
146
:
540
-
548
.

87

Yoshida
N
,
Yuasa
M
,
Sovannarith
T
et al.
A cross-sectional investigation for verification of globalization of falsified medicines in Cambodia, indicated by tablets of sildenafil citrate
.
Pharmacy (Basel)
2019
;
7
:

88

Dos Santos
MK
,
de Cassia Mariotti
K
,
Kahmann
A
et al.
Comparison between counterfeit and authentic medicines: A novel approach using differential scanning calorimetry and hierarchical cluster analysis
.
J Pharm Biomed Anal
2019
;
166
:
304
-
309
.

89

Falco
LFG
,
Melo
C
,
de Oliveira
DN
et al.
An LDI-MSI approach for targeted and untargeted differentiation and assessment of pharmaceutical formulations
.
Talanta
2019
;
197
:
92
-
97
.

90

Sabin
GP
,
Lozano
VA
,
Rocha
WF
et al.
Characterization of sildenafil citrate tablets of different sources by near infrared chemical imaging and chemometric tools
.
J Pharm Biomed Anal
2013
;
85
:
207
-
212
.

91

Deconinck
E
,
Andriessens
S
,
Bothy
JL
et al.
Comparative dissolution study on counterfeit medicines of PDE-5 inhibitors
.
J Pharm Anal
2014
;
4
:
250
-
257
.

92

Nagasawa
S
,
Saka
K
,
Yamagishi
Y
et al.
Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors
.
Leg Med (Tokyo)
2021
;
48
:
101815

93

Wiseman
JM
,
Laughlin
BC.
Desorption electrospray ionization (DESI) mass spectrometry: A brief introduction and overview
.
Curr Separat Drug Dev
2007
;
22
:
11
-
14
.

94

Rajh Vidal
DT
,
Augelli
MA
,
Lucio do Lago
C.
Determination of sildenafil and vardenafil by capillary zone electrophoresis using capacitively coupled contactless conductivity detection
.
Anal Methods
2013
;
5
:
2041
-
2045
.

95

Azizi
A
,
Tengah
A
,
Petalcorin
MIR.
Developing a phosphodiesterase-5 inhibitor assay to detect counterfeit drugs containing phosphodiesterase-5 inhibitors using spectrophotometry
.
F1000 Res
2019
;
8
:
1692
.

96

Coic
L
,
Sacre
PY
,
Dispas
A
et al.
Comparison of hyperspectral imaging techniques for the elucidation of falsified medicines composition
.
Talanta
2019
;
198
:
457
-
463
.

97

Beasley
E
,
Suman
M
,
Coleman
T.
The use of high performance anion exchange chromatography for the detection of counterfeit pharmaceutical products using the excipient content as a marker
.
Fields: J Huddersfield Student Res
2015
;
1
:
1
.

98

Ahmed
A
,
Abdellah
N
,
Shaltout
E.
Gas Chromatography-mass spectrometric analysis of a counterfeit sildenafil product and its potential hepatotoxicity in mice
.
Mansoura J Forensic Med Clin Toxicol
2019
;
27
:
43
-
56
.

99

Meehl OJ. A first study on the suitability of volume holograms for use as integral security features on pharmaceuticals. Available at:  http://rave.ohiolink.edu/etdc/view?acc_num=osu1593622852698023. Accessed August 6, 2021.

100

Reis
NFA
,
Silva
LFG
,
Souza
M
et al.
UHPLC for quality evaluation of genuine and illegal medicines containing sildenafil citrate and tadalafil
.
J Chromatogr Sci
2021
;
59
:
30
-
39
.

101

Lee
S
,
Choi
B
,
Kim
J
et al.
An LC-MS/MS method for the determination of five erectile dysfunction drugs and their selected metabolites in hair
.
J Chromatogr B Analyt Technol Biomed Life Sci
2015
;
978-979
:
1
-
10
.

102

Tero-Vescan
A
,
Vari
C
,
Filip
C
et al.
Analysis of dietary supplements and drugs for erectile dysfunction by HPLCUV
.
Acta Med Transilvanica
2014
;
II
:
297
-
299
.

103

Coelho Neto
J
,
Faraco
RFP
,
Alves
CF
et al.
Genuine sildenafil tablets sold in Brazil disguised as MDMA
.
Forensic Sci Int
2018
;
283
:
e8
-
e12
.

104

Pereira
LSA
,
Lisboa
FLC
,
Coelho Neto
J
et al.
Screening method for rapid classification of psychoactive substances in illicit tablets using mid infrared spectroscopy and PLS-DA
.
Forensic Sci Int
2018
;
288
:
227
-
235
.

105

Kerpel dos Santos
M
,
Araujo dos Santos
N
,
Allochio Filho
JF
et al.
Paper spray ionization coupled to Fourier transform ion cyclotron resonance mass spectrometry as a tool to fight the counterfeiting of medicines
.
Int J Mass Spectrom
2021
;
468
:
116649
.

106

Deliwala
S
,
Haykal
T
,
Dhillon
H
et al.
ST-elevation myocardial infarction and complete heart block in a nitrate-free patient using a new emerging substance called rhino
.
Cureus
2020
;
12
:
e7601
.

107

Kuramoto
N
,
Yabe
D
,
Kurose
T
et al.
A case of hypoglycemia due to illegitimate sexual enhancement medication
.
Diabetes Res Clin Pract
2015
;
108
:
e8
-
e10
.

108

Nissan
R
,
Poperno
A
,
Stein
GY
et al.
A case of hepatotoxicity induced by adulterated "Tiger King", a Chinese herbal medicine containing sildenafil
.
Curr Drug Saf
2016
;
11
:
184
-
188
.

109

Ross
JA
,
Downs
JW
,
Bazydlo
LA
et al.
Outbreak of severe hypoglycemia after ingestion of a male enhancement supplement - Virginia, august-november 2019
.
MMWR Morb Mortal Wkly Rep
2020
;
69
:
740
-
743
.

110

Dyer
C.
Internet supplier of fake Viagra is ordered to pay back 14.4m pound
.
BMJ
2012
;
344
:
e3103
.

111

Gibson
L.
Counterfeits of impotence drug appear in the United Kingdom
.
BMJ
2004
;
329
:
532
.

112

Hellstrom
WJ.
The growing concerns regarding counterfeit medications
.
J Sex Med
2011
;
8
:
1
-
3
.

113

Liang
BA
,
Mackey
TK.
Sexual medicine: Online risks to health–the problem of counterfeit drugs
.
Nat Rev Urol
2012
;
9
:
480
-
482
.

114

The
L.
Combating counterfeit drugs
.
Lancet
2008
;
371
:
1551
.

115

McMahon
CG.
Get a better erection!–Hope for sale–use sexual snake oil
.
J Sex Med
2010
;
7
:
1699
-
1702
.

116

ElAmrawy
F
,
ElAgouri
G
,
Elnoweam
O
et al.
Adulterated and counterfeit male enhancement nutraceuticals and dietary supplements pose a real threat to the management of erectile dysfunction: A global perspective
.
J Diet Suppl
2016
;
13
:
660
-
693
.

117

Hatzimouratidis
K
,
Salonia
A
,
Adaikan
G
et al.
Pharmacotherapy for erectile dysfunction: Recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015)
.
J Sex Med
2016
;
13
:
465
-
488
.

118

Lowe
G
,
Costabile
R.
Phosphodiesterase type 5 inhibitor abuse: a critical review
.
Curr Drug Abuse Rev
2011
;
4
:
87
-
94
.

119

Shah
RY
,
Prajapati
PN
,
Agrawal
YK.
Anticounterfeit packaging technologies
.
J Adv Pharm Technol Res
2010
;
1
:
368
-
373
.

120

Sugita
M
,
Miyakawa
M.
Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example
.
Environ Health Prev Med
2010
;
15
:
244
-
251
.

121

Yafi
FA
,
Sharlip
ID
,
Becher
EF.
Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
.
Sex Med Rev
2018
;
6
:
242
-
252
.

122

Yelehe-Okouma
M
,
Pape
E
,
Humbertjean
L
et al.
Drug adulteration of sexual enhancement supplements: A worldwide insidious public health threat
.
Fundam Clin Pharmacol
2021
;
35
:
792
-
807
.

123

Ziance
RJ.
Roles for pharmacy in combatting counterfeit drugs
.
J Am Pharm Assoc (2003)
2008
;
48
:
e71
-
e88
.
quiz e89-91

124

Dorsey
P
,
Keel
C
,
Klavens
M
et al.
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
.
Expert Opin Pharmacother
2010
;
11
:
1109
-
1122
.

125

Jackson
G
,
Patel
S
,
Khan
S.
Assessing the problem of counterfeit medications in the United Kingdom
.
Int J Clin Pract
2012
;
66
:
241
-
250
.

126

McVeigh
J
,
Evans-Brown
M
,
Bellis
MA.
Human enhancement drugs and the pursuit of perfection
.
Adicciones
2012
;
24
:
185
-
190
.

127

Blackstone
EA
,
Fuhr
JP
Jr.
,
Pociask
S.
The health and economic effects of counterfeit drugs
.
Am Health Drug Benefits
2014
;
7
:
216
-
224
.

128

Israel J, Laborde EL. (2016) Alternative and internet drugs that affect sexual function. In: Köhler T, McVary K, editors. Contemporary treatment of erectile dysfunction. Contemporary Endocrinology. Humana Press, Cham. Available at:  https://doi.org/10.1007/978-3-319-31587-4_10. Accessed August 6, 2021.

129

Capogrosso
P
,
Ventimiglia
E
,
Oreggia
D
et al.
Medical treatment of erectile dysfunction: Too many medical prescriptions?
Urologia
2017
;
84
:
121
-
129
.

130

Marlyna
H
,
Sardjono
A.
Research report on the knowledge, experience, and attitude of consumers towards counterfeit medicine in Jakarta: A legal analysis
.
Harkrisnowo
H
,
Juwana
H
,
Oppusunggu
Y
.
Law and justice in a globalized world
London, UK
:
Taylor & Francis
,
2018
.
15
-
22
.

131

Ouranidis
A
,
Tsiaxerli
A
,
Vardaka
E
et al.
Sildenafil 4.0-integrated synthetic chemistry, formulation and analytical strategies effecting immense therapeutic and societal impact in the fourth industrial era
.
Pharmaceuticals (Basel)
2021
;
14
:
365
.

132

Santos
ADC
,
Dutra
LM
,
Menezes
LRA
et al.
Forensic NMR spectroscopy: Just a beginning of a promising partnership
.
TrAC Trends Analyt Chem
2018
;
107
:
31
-
42
.

133

Nneka
O
,
Olivia
O.
Investigation of consumers' knowledge about NAFDAC media campaign on consuming counterfeit drugs and substandard food in South East Nigeria
.
IIARD Int J Econ Business Manag
2020
;
6
:
60
-
76
.

134

Singh
S
,
Prasad
B
,
Savaliya
A
et al.
Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs
.
TrAC Trends Analyt Chem
2009
;
28
:
13
-
28
.

135

Ames
J
,
Souza
DZ.
Counterfeiting of drugs in Brazil
.
Rev Saude Publica
2012
;
46
:
154
-
159
.

136

Kimura
M
,
Shimura
S
,
Kobayashi
H
et al.
Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: Data from the nationwide Japanese population
.
J Sex Med
2012
;
9
:
1649
-
1658
.

137

U.S. Food and Drug Administration. Counterfeit medicine.

138

Mulhall
JP
,
Giraldi
A
,
Hackett
G
et al.
The 2018 revision to the process of Care Model for evaluation of erectile dysfunction
.
J Sex Med
2018
;
15
:
1280
-
1292
.

139

Hackett
G
,
Kirby
M
,
Wylie
K
et al.
British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men-2017
.
J Sex Med
2018
;
15
:
430
-
457
.

140

Porst
H
,
Burnett
A
,
Brock
G
et al.
SOP conservative (medical and mechanical) treatment of erectile dysfunction
.
J Sex Med
2013
;
10
:
130
-
171
.

141

Sansone
A
,
Aversa
A
,
Corona
G
et al.
Management of premature ejaculation: A clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS)
.
J Endocrinol Invest
2020
;
44
:
1103
-
1118
.

142

Salonia
A
,
Bettocchi
C
,
Boeri
L
et al.
European Association of Urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction
.
Eur Urol
2021
;
80
:
333
-
357
.

143

Kao
SL
,
Chan
CL
,
Tan
B
et al.
An unusual outbreak of hypoglycemia
.
N Engl J Med
2009
;
360
:
734
-
736
.

144

Nagasawa
S
,
Saka
K
,
Yamagishi
Y
et al.
Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors
.
Leg Med
2021
;
48
:
101805
.

145

Corona
G
,
Sansone
A
,
Pallotti
F
et al.
People smoke for nicotine, but lose sexual and reproductive health for tar: A narrative review on the effect of cigarette smoking on male sexuality and reproduction
.
J Endocrinol Invest
2020
;
43
:
1391
-
1408
.

146

Sansone A, Limoncin E, Colonnello E, et al. Harm reduction in sexual medicine. Sex Med Rev 2021. doi:  10.1016/j.sxmr.2021.01.005. E-pub ahead of print.

147

Sansone
A
,
Romanelli
F
,
Gianfrilli
D
et al.
Endocrine evaluation of erectile dysfunction
.
Endocrine
2014
;
46
:
423
-
430
.

148

Sansone
 
A
,
Kliesch
 
S
,
Dugas
 
M
, et al.  
Serum concentrations of dihydrotestosterone are associated with symptoms of hypogonadism in biochemically eugonadal men
.
J Endocrinol Invest.
 
2021
. doi: 10.1007/s40618-021-01561-0. E-pub ahead of print.

149

Sansone A, Mollaioli D, Ciocca G, et al. Sexual dysfunction in men and women with diabetes: A mirror of their complications? Curr Diabetes Rev. 2021. doi:  10.2174/1573399817666210309104740. E-pub ahead of print.

150

Jannini
EA.
SM = SM: The interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner
.
Sex Med Rev
2017
;
5
:
349
-
364
.

151

Sansone
A
,
Cignarelli
A
,
Sansone
M
et al.
Serum homocysteine levels in men with and without erectile dysfunction: A systematic review and meta-analysis
.
Int J Endocrinol
2018
;
2018
:
7424792

152

Corona
G
,
Rastrelli
G
,
Monami
M
et al.
Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: Cross-sectional and longitudinal analyses
.
Andrology
2013
;
1
:
864
-
871
.

153

Foresta
C
,
Caretta
N
,
Corona
G
et al.
Clinical and metabolic evaluation of subjects with erectile dysfunction: A review with a proposal flowchart
.
Int J Androl
2009
;
32
:
198
-
211
.

154

Mollaioli
D
,
Ciocca
G
,
Limoncin
E
et al.
Lifestyles and sexuality in men and women: The gender perspective in sexual medicine
.
Reprod Biol Endocrinol
2020
;
18
:
10
.

155

Symonds
T
,
Dean
JD
,
Carr
A
et al.
A feasibility study comparing pharmacist and physician recommendations for sildenafil treatment
.
J Sex Med
2011
;
8
:
1463
-
1471
.

156

Lombardo
S
,
Marino
F
,
Cosentino
M.
A nationwide web-based survey of a sample of Italian community pharmacists' perceptions and opinions about online sales of medicines and falsified drugs
.
Pharm Pract (Granada)
2019
;
17
:
1593
.

157

Barrett
R.
Evaluation of community pharmacists' readiness to implement the Falsified Medicines Directive (Directive 2011/62/EC): An English cross-sectional survey with geospatial analysis
.
BMJ Open
2020
;
10
:
e033405

158

Romanelli
F
,
Sansone
A
,
Lenzi
A.
Erectile dysfunction in aging male
.
Acta Biomed
2010
;
81
:
Suppl 1
:
89
-
94
.

159

Bechara
A
,
Casabe
A
,
De Bonis
W
et al.
Recreational use of phosphodiesterase type 5 inhibitors by healthy young men
.
J Sex Med
2010
;
7
:
3736
-
3742
.

160

Korkes
F
,
Costa-Matos
A
,
Gasperini
R
et al.
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students
.
J Sex Med
2008
;
5
:
2414
-
2418
.

161

Schnetzler
G
,
Banks
I
,
Kirby
M
et al.
Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors
.
J Sex Med
2010
;
7
:
1237
-
1246
.

162

Jannini
EA
,
Sternbach
N
,
Limoncin
E
et al.
Health-related characteristics and unmet needs of men with erectile dysfunction: A survey in five European countries
.
J Sex Med
2014
;
11
:
40
-
50
.

163

Corona
G
,
Rastrelli
G
,
Burri
A
et al.
First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis
.
Andrology
2016
;
4
:
1002
-
1009
.

164

Guo
J
,
Wang
F
,
Zhou
Q
et al.
Safety and efficacy of traditional Chinese medicine, Qiaoshao formula, combined with dapoxetine in the treatment of premature ejaculation: An open-label, real-life, retrospective multicentre study in Chinese men
.
Andrologia
2021
;
53
:
e13915
.

165

Caggiano
C
,
Guida
E
,
Todaro
F
et al.
Sempervirine inhibits RNA polymerase I transcription independently from p53 in tumor cells
.
Cell Death Discov
2020
;
6
:
111
.

166

Festuccia
C
,
Mancini
A
,
Gravina
GL
et al.
Antitumor effects of saffron-derived carotenoids in prostate cancer cell models
.
Biomed Res Int
2014
;
2014
:
135048

167

Kamenov
Z
,
Fileva
S
,
Kalinov
K
et al.
Evaluation of the efficacy and safety of Tribulus terrestris in male sexual dysfunction–A prospective, randomized, double-blind, placebo-controlled clinical trial
.
Maturitas
2017
;
99
:
20
-
26
.

168

Jannini
EA
,
Lenzi
A.
Sexual dysfunction: Is acupuncture a therapeutic option for premature ejaculation?
Nat Rev Urol
2011
;
8
:
235
-
236
.

169

Virag
R.
Intracavernous injection of papaverine for erectile failure
.
Lancet
1982
;
2
:
938
.

170

U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers.

171

Minghetti
P
,
Pantano
D
,
Gennari
CG
et al.
Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe
.
Health Policy
2014
;
117
:
328
-
333
.

172

Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections – Case count. Available at:
 https://www.cdc.gov/hai/outbreaks/meningitis.html. Accessed August 6, 2021.

173

Kauffman
CA
,
Pappas
PG
,
Patterson
TF.
Fungal infections associated with contaminated methylprednisolone injections
.
N Engl J Med
2013
;
368
:
2495
-
2500
.

174

Pratchett
T.
Going postal
.
London, UK
:
Transworld
,
2008
.

175

European Commission. Falsified medicines. 2021. Available at:  https://ec.europa.eu/health/human-use/falsified_medicines_en. Accessed August 6, 2021.

176

World Health Organization. Medical product alert N°2/2021: Falsified COVID-19 vaccine BNT162b2. 2021.

177

Venhuis
BJ
,
Mosimann
R
,
Wijnberg
B.
Medicrime convention: Against falsified medical products
.
Lancet
2015
;
386
:
855
-
856
.

178

Council of Europe. Chart of signature and ratifications of treaty 211. 2021. Available at:https://www.coe.int/en/web/conventions/full-list?module=signatures-by-treaty&treatynum=211. Accessed August 6, 2021.

179

U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. 2020. Available at:https://www.fda.gov/drugs/quick-tips-buying-medicines-over-internet/besaferx-your-source-online-pharmacy-information. Accessed August 6, 2021.

180

Italian Medicines Agency. Fakeshare. 2020. Available at:  http://www.fakeshare.eu/en/partners/aifa-italian-medicines-agency. Accessed August 6, 2021.

181

Mackey
T
,
Kalyanam
J
,
Klugman
J
et al.
Solution to detect, classify, and report illicit online marketing and sales of controlled substances via twitter: using machine learning and web forensics to combat digital opioid access
.
J Med Internet Res
2018
;
20
:
e10029
.

182

Dooley
AB
,
Houssaye
N
,
Baum
N.
Use of telemedicine for sexual medicine patients
.
Sex Med Rev
2020
;
8
:
507
-
517
.

183

Rabinowitz
MJ
,
Kohn
TP
,
Ellimoottil
C
et al.
The impact of telemedicine on sexual medicine at a Major Academic Center during the COVID-19 pandemic
.
Sex Med
2021
;
9
:
100366

184

Russo
GI
,
di Mauro
M
,
Cocci
A
et al.
Consulting "Dr Google" for sexual dysfunction: A contemporary worldwide trend analysis
.
Int J Impot Res
2020
;
32
:
455
-
461
.

185

Kirana
PS
,
Gudeloglu
A
,
Sansone
A
et al.
E-sexual health: A position statement of the European Society for Sexual Medicine
.
J Sex Med
2020
;
17
:
1246
-
1253
.

186

Paxton
M.
Current challenges with supply-chain integrity and the threat to the quality of marketed drugs
.
Clin Pharmacol Ther
2011
;
89
:
316
-
319
.

187

Scaglione
F
,
Donde
S
,
Hassan
TA
et al.
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: Pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation
.
Clin Ther
2017
;
39
:
370
-
377
.

188

Jannini
EA
,
Droupy
S.
Needs and expectations of patients with erectile dysfunction: An update on pharmacological innovations in phosphodiesterase type 5 inhibition with focus on sildenafil
.
Sex Med
2019
;
7
:
1
-
10
.

189

Karki
S
,
Kim
H
,
Na
S-J
et al.
Thin films as an emerging platform for drug delivery
.
Asian J Pharm Sci
2016
;
11
:
559
-
574
.

190

Trenfield
SJ
,
Xian Tan
H
,
Awad
A
et al.
Track-and-trace: Novel anti-counterfeit measures for 3D printed personalized drug products using smart material inks
.
Int J Pharm
2019
;
567
:
118443
.

191

Borges
AF
,
Silva
C
,
Coelho
JFJ
et al.
Oral films: Current status and future perspectives
.
J Control Release
2015
;
206
:
1
-
19
.

192

Borges
AF
,
Silva
C
,
Coelho
JFJ
et al.
Oral films: Current status and future perspectives II – Intellectual property, technologies and market needs
.
J Control Release
2015
;
206
:
108
-
121
.

193

Goel
H
,
Rai
P
,
Rana
V
et al.
Orally disintegrating systems: Innovations in formulation and technology
.
Recent Pat Drug Deliv Formul
2008
;
2
:
258
-
274
.

194

Cocci
A
,
Capece
M
,
Cito
G
et al.
Effectiveness and safety of oro-dispersible sildenafil in a new film formulation for the treatment of erectile dysfunction: Comparison between sildenafil 100-mg film-coated tablet and 75-mg oro-dispersible film
.
J Sex Med
2017
;
14
:
1606
-
1611
.

195

Radicioni
M
,
Castiglioni
C
,
Giori
A
et al.
Bioequivalence study of a new sildenafil 100 mg orodispersible film compared to the conventional film-coated 100 mg tablet administered to healthy male volunteers
.
Drug Des Devel Ther
2017
;
11
:
1183
-
1192
.

196

Isidori
AM
,
Giammusso
B
,
Corona
G
et al.
Diagnostic and therapeutic workup of erectile dysfunction: Results from a Delphi consensus of andrology experts
.
Sex Med
2019
;
7
:
292
-
302
.

Author notes

Conflict of Interests: EAJ has been speaker and or paid consultant for Bayer, Ibsa, Lundbeck, Menarini, Otsuka, Pfizer, Shionogi, and Viatris. The other authors have no conflict of interests to declare.